---
title: "Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli"
id: "medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1?rss=1"
published_at: "2026-11-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1?rss=1)
- **Published At:** 2026-11-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators performed a systematic review and random-effects meta-analysis of cohort and case-control reports assessing **metformin** exposure and incident **breast cancer**, searching PubMed and prior meta-analyses up to 1 November 2026. - The team prioritized one report per source population and classified studies by whether they used new-user designs, time-varying exposure analyses, or target trial emulation to address time-related biases. - Twenty-two reports from 15 source populations met eligibility; 12 independent studies were pooled using a DerSimonian-Laird model. - The pooled relative risk (RR) across all pooled studies was 0.89 (95% CI 0.74–1.07) with high heterogeneity (I-squared = 90.5%). - In the nine studies that explicitly addressed time-related biases, the pooled RR was 1.00 (95% CI 0.94–1.08) with no heterogeneity (I-squared = 0%). - In studies that did not address or were unclear about time-related biases, the pooled RR was 0.69 (95% CI 0.56–0.84); subgroup difference testing produced Q = 12.78 (p = 0.0004). - Reclassifying the single unclear study removed the statistical between-group difference (Q = 1.15, p = 0.28). - For **imeglimin**, the authors found no clinical study reporting breast cancer or any cancer outcome; the PubMed and registry searches returned preclinical reports and no evaluable clinical cancer outcomes, so no meta-analysis was possible. - The authors calculated that a comparative new-user cohort would need roughly 631 breast cancer events to detect an HR of 0.80, indicating the requirement for an adequately powered observational design. - Data, extraction tables, bias assessments, and Python code are provided as Supplementary Data; protocol registration (PROSPERO) details and protocol deviations are reported in Methods.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=GfgEh.pWa7cFGbBtNLxlV7qQ1Dnnbl_4Is9MQeuljTg-1793651218.0065844-1.2.1.1-aYu4TR4lKfyU9Mr8OEmAZeSfuKKOJav8vKQ6R.7FfJX5Hnv8vaEBQitthXRkxoEb) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Metformin use and the risk of incident breast cancer: a systematic review and meta-analysis accounting for time-related biases, and why imeglimin cannot yet be evaluated Misuzu Akieda, Yuta Horita, Hiroyoshi Harada, Masayoshi Mori, Yusuke Murata, [ View ORCID Profile](http://orcid.org/0000-0002-1958-7572)Kenji Ohe doi: https://doi.org/10.64898/2026.11.01.26367001 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Misuzu Akieda Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Misuzu%2BAkieda%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Akieda%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMisuzu%2BAkieda%2B) Yuta Horita Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yuta%2BHorita%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Horita%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYuta%2BHorita%2B) Hiroyoshi Harada Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hiroyoshi%2BHarada%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Harada%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHiroyoshi%2BHarada%2B) Masayoshi Mori Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Masayoshi%2BMori%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mori%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMasayoshi%2BMori%2B) Yusuke Murata Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yusuke%2BMurata%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Murata%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYusuke%2BMurata%2B) Kenji Ohe Faculty of Pharmaceutical Sciences, Fukuoka University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kenji%2BOhe%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ohe%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKenji%2BOhe%2B) * [ORCID record for Kenji Ohe](http://orcid.org/0000-0002-1958-7572 "Open in new tab") * For correspondence: ohekenji@fukuoka-u.ac.jp * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1336530/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1336530/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1336530/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1336530/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1336530/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Observational studies have suggested that metformin lowers breast cancer risk, but many were susceptible to immortal time and time-window bias. Imeglimin, a structurally related glucose-lowering drug approved in Japan in 2021, has been proposed as a candidate for cancer prevention. Methods: We searched PubMed (1 November 2026) and the reference lists of earlier meta-analyses for cohort and case-control studies that reported breast cancer-specific estimates for metformin use and incident breast cancer. One report per source population was pooled with a DerSimonian-Laird random-effects model. Studies were classified by whether they addressed time-related biases, using a new-user design, time-varying exposure or target trial emulation. For imeglimin, we applied the same criteria in a systematic search of PubMed and ClinicalTrials.gov, assessed whether a meta-analysis was feasible, and reviewed non-clinical and structural data. Results: The search identified 368 PubMed records and 28 reports from other sources. Twenty-two reports from 15 source populations were eligible, and 12 independent studies were pooled. The pooled relative risk (RR) was 0.89 (95% CI 0.74-1.07; I-squared = 90.5%). In nine studies that addressed time-related biases, the RR was 1.00 (0.94-1.08; I-squared = 0%). In three that did not, or were unclear, it was 0.69 (0.56-0.84); the between-group difference was Q = 12.78, p = 0.0004. The difference was not significant when the one unclear study was reclassified (Q = 1.15, p = 0.28). For imeglimin, the search returned 218 PubMed records and 10 registered studies, but no clinical study reported breast cancer or any cancer outcome. No meta-analysis was possible. The available evidence consisted of one in vitro study in breast cancer cells, one docking study, and models of other cancers at concentrations at least about 40-fold above clinical plasma levels. A comparative cohort would need about 631 breast cancer events to detect a hazard ratio of 0.80. Conclusions: In studies that addressed time-related biases, metformin use was not associated with incident breast cancer. A meta-analysis of imeglimin and breast cancer is not yet possible, because no clinical study exists and exposure time since approval is short. Its structural relation to metformin does not by itself predict a preventive effect. The next step should be an adequately powered new-user, active-comparator cohort study. Registration: PROSPERO CRD420261301586 (submitted 6 February 2026; registered 1 November 2026). Deviations from the protocol are reported in the Methods. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data from previously published studies indexed in PubMed (https://pubmed.ncbi.nlm.nih.gov/). All source publications are cited in the manuscript and listed with their PMIDs/DOIs in Table 1 and Supplementary Data. Only aggregate published estimates were used; no individual participant data were accessed, so ethics committee approval was not required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data used in this study were extracted from previously published articles, which are cited in the manuscript and listed with their PMIDs/DOIs in Table 1. The full extraction table (with the source location of every estimate), the PubMed search record and list of retrieved PMIDs, the risk-of-bias assessment, the list of excluded reports, and the Python analysis code are provided as Supplementary Data. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.30.26366523v2 "Lymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplogroup and Clinical Outcome in Advanced Melanoma") Posted November 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/02/2026.11.01.26367001.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.01.26367001v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/02/2026.11.01.26367001.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Metformin use and the risk of incident breast cancer: a systematic review and meta-analysis accounting for time-related biases, and why imeglimin cannot yet be evaluated Misuzu Akieda, Yuta Horita, Hiroyoshi Harada, Masayoshi Mori, Yusuke Murata, Kenji Ohe medRxiv 2026.11.01.26367001; doi: https://doi.org/10.64898/2026.11.01.26367001 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.01.26367001v1%26text%3DMetformin%2520use%2520and%2520the%2520risk%2520of%2520incident%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520accounting%2520for%2520time-related%2520biases%252C%2520and%2520why%2520imeglimin%2520cannot%2520yet%2520be%2520evaluated "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.01.26367001v1%26t%3DMetformin%2520use%2520and%2520the%2520risk%2520of%2520incident%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520accounting%2520for%2520time-related%2520biases%252C%2520and%2520why%2520imeglimin%2520cannot%2520yet%2520be%2520evaluated "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.01.26367001v1%26title%3DMetformin%2520use%2520and%2520the%2520risk%2520of%2520incident%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520accounting%2520for%2520time-related%2520biases%252C%2520and%2520why%2520imeglimin%2520cannot%2520yet%2520be%2520evaluated%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.01.26367001v1%26title%3DMetformin%2520use%2520and%2520the%2520risk%2520of%2520incident%2520breast%2520cancer%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520accounting%2520for%2520time-related%2520biases%252C%2520and%2520why%2520imeglimin%2520cannot%2520yet%2520be%2520evaluated "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.01.26367001) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.01.26367001v1&count=horizontal&via=&text=Metformin%20use%20and%20the%20risk%20of%20incident%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20accounting%20for%20time-related%20biases%2C%20and%20why%20imeglimin%20cannot%20yet%20be%20evaluated&counturl=www.medrxiv.org/content/10.64898/2026.11.01.26367001v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (917) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (348) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4977) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (493) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (426) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (675) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1684) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16221) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1239) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7259) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5265) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1464) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1826) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1378) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16470) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1199) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (697) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (749) * [Neurology](https://www.medrxiv.org/collection/neurology) (7557) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1121) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1293) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1038) * [Oncology](https://www.medrxiv.org/collection/oncology) (3735) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1088) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (407) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (464) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (499) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (720) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1854) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (753) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (785) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6107) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9963) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2517) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1509) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1265) *
## Related Clinical Research

- [Targeting VISTA for Skin Cancer Immunotherapy: Source Article Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-vista-as-a-novel-immunotherapy-for-skin-cancer.md)
- [Metformin alters HMGA1a and RBM3 in breast cancer cells; ESR1 splicing effect varies with density](https://medichelpline.com/clinical-feed/biorxiv-6-metformin-lowers-hmga1a-and-rbm3-protein-in-breast-cancer-cells-and-its-effect.md)
- [Metabolic reprogramming in the immune microenvironment of Ewing sarcoma — article page summary](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from.md)
- [YTHDF2 promotes cutaneous melanoma progression via m6A-dependent HMOX1 regulation of ferroptosis](https://medichelpline.com/clinical-feed/pubmed-42848283.md) (DOI: 10.1007/s12032-026-03427-y)
- [Gum acacia–gelatin nanohydrogel co-delivering metformin and doxorubicin inhibits TNT-driven breast](https://medichelpline.com/clinical-feed/pubmed-42605874.md) (DOI: 10.1039/d6bm00697c)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.